Immunosuppressants drugs for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Amra IRCT20170207032444N3		RCT	thalidomide	standard of care	COVID-19 severe or critically	high	30/30	inconclusive
Kumar CTRI/2020/05/024959		RCT	itolizumab	standard of care	COVID-19 severe or critically	high	22/10	inconclusive
CAN-COVID NCT04362813		RCT	canakinumab	placebo	COVID-19 severe or critically	some concern	227/227	inconclusive	inconclusive 39 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis